Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|European Journal of Cancer|2019Cited by 92
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|The Oncologist|2020Cited by 25
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|Journal of the Formosan Medical Association|2024Cited by 5
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trialYao-Wen Kuo, Hao‐Chien Wang, Yen‐Lin Chen et al.|European Respiratory Journal|2025Cited by 1
Impact of PD-L1 Expression and Tumor Microenvironments on Osimertinib Efficacy in Pretreated Non-Small-Cell Lung Cancer Harboring an Acquired EGFRT790M MutationChing‐Yao Yang, Chong‐Jen Yu, Wei‐Yu Liao et al.|SSRN Electronic Journal|2022Cited by 0